{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:11:16Z","timestamp":1774926676391,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>There are few data about the effectiveness and safety of angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan in end-stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD). The present study was conducted to evaluate the association between sacubitril-valsartan treatment and peritoneal ultrafiltration (PUF) in PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>Forty-seven ESRD patients undergoing PD for at least 3 months without severe congestive heart failure (CHF) were included in this study. Sacubitril-valsartan (generally 100 mg b.i.d) was administered after consultation with the nephrologist. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) were required to be discontinued 36 h before prescribing sacubitril-valsartan. Other treatments and dialysis modality did not change. Baseline demographic and clinical parameters were collected before ARNI administration, and daily PUF, urine volume, total output, blood pressure (BP), and body weight were collected within 7 days before and after ARNI treatment. After treated with sacubitril-valsartan, 30 patients (63.8%) had a significant increase of PUF [up to 150.4 (110.7, 232.1) ml per day], while the remaining 17 (36.2%) had a slight decrease. The overall increase of PUF was 66.4 (21.4, 123.2) ml\/24 h within the 7 days after sacubitril-valsartan administration, which was significantly higher than those before (<jats:italic>P<\/jats:italic> = 0.004). Total output, BP, and body weight also significantly improved. No adverse drug reactions were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study indicated that sacubitril-valsartan was associated with the increase of short-term PUF and total output in PD patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.831541","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:04:06Z","timestamp":1654232646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Sacubitril-Valsartan Increases Ultrafiltration in Patients Undergoing Peritoneal Dialysis: A Short-Term Retrospective Self-Controlled Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Fen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1021\/jm00010a014","article-title":"Dicarboxylic acid dipeptide neutral endopeptidase inhibitors","volume":"38","author":"Ksander","year":"1995","journal-title":"J Med Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/dmd.115.068536","article-title":"Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation","volume":"44","author":"Shi","year":"2016","journal-title":"Drug Metab Dispos."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41540-017-0013-4","article-title":"Mechanisms of action of sacubitril\/valsartan on cardiac remodeling: a systems biology approach","volume":"3","author":"Iborra-Egea","year":"2017","journal-title":"NPJ Syst Biol Appl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"657067","DOI":"10.3389\/fmed.2021.657067","article-title":"Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis","volume":"8","author":"Fu","year":"2021","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension."},{"key":"B12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/hr.2015.1","article-title":"Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction","volume":"38","author":"Ito","year":"2015","journal-title":"Hypertens Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jch.12667","article-title":"LCZ696, a First-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertension","volume":"18","author":"Kario","year":"2016","journal-title":"J Clin Hypertens."},{"key":"B14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/jch.13437","article-title":"Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study","volume":"20","author":"Huo","year":"2018","journal-title":"J Clin Hypertens."},{"key":"B15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension."},{"key":"B17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail."},{"key":"B18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11897-016-0292-x","article-title":"Neprilysin and natriuretic peptide regulation in heart failure","volume":"13","author":"Bayes-Genis","year":"2016","journal-title":"Curr Heart Fail Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","article-title":"Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension","volume":"69","author":"Wang","year":"2017","journal-title":"Hypertension."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1046\/j.1523-1755.1998.00181.x","article-title":"Ho-dac-Pannekeet MM, Struijk DG. augmenting solute clearance in peritoneal dialysis","volume":"54","author":"Krediet","year":"1998","journal-title":"Kidney Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2215\/CJN.07480618","article-title":"Assessment and management of hypertension among patients on peritoneal dialysis","volume":"14","author":"Vaios","year":"2019","journal-title":"Clin J Am Soc Nephro."},{"key":"B22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3747\/pdi.2013.00092","article-title":"Effect of peritoneal dialysis on respiratory mechanics in acute kidney injury patients","volume":"34","author":"Almeida","year":"2014","journal-title":"Perit Dial Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3747\/pdi.2012.00290","article-title":"Peritoneal ultrafiltration in refractory heart failure: a cohort study","volume":"34","author":"Bertoli","year":"2014","journal-title":"Perit Dial Int:."},{"key":"B24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2369-14-117","article-title":"B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function","volume":"14","author":"Jafri","year":"2013","journal-title":"BMC Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. an expert consensus meeting report of the heart failure association of the European society of cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B26","first-page":"S192","article-title":"national kidney foundation-dialysis outcomes quality initiative","volume":"30","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.scitotenv.2016.12.032","article-title":"Validation of integrated water vapor from OMI satellite instrument against reference GPS data at the Iberian Peninsula","volume":"580","author":"Vaquero-Martinez","year":"2017","journal-title":"Sci Total Environ."},{"key":"B28","first-page":"34","volume-title":"Nonparametric Statistical Methods.","author":"Hollander","year":"1973"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1136\/heartjnl-2016-310794","article-title":"Heart failure in patients with kidney disease","volume":"103","author":"Tuegel","year":"2017","journal-title":"Heart."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the hope randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1525-139X.2003.160271.x","article-title":"Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure","volume":"16","author":"Foley","year":"2003","journal-title":"Semin Dialysis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000380915","article-title":"Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review","volume":"5","author":"Lu","year":"2015","journal-title":"Cardiorenal Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00467-007-0541-z","article-title":"Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis","volume":"23","author":"Fusshoeller","year":"2008","journal-title":"Pediatr Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/sj.ki.5001506","article-title":"Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane","volume":"69","author":"Noh","year":"2006","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/089686080502500502","article-title":"Impact of glucose in peritoneal dialysis: saint or sinner?","volume":"25","author":"Sitter","year":"2005","journal-title":"Perit Dial Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1681\/ASN.V132470","article-title":"Morphologic changes in the peritoneal membrane of patients with renal disease","volume":"13","author":"Williams","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"i2","DOI":"10.1093\/ndt\/gfl183","article-title":"Epithelial-to-mesenchymal transition of the mesothelial cell\u2014its role in the response of the peritoneum to dialysis","volume":"21","author":"Selgas","year":"2006","journal-title":"Nephrol Dial Transpl."},{"key":"B41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/Valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/eci.12234","article-title":"Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship","volume":"44","author":"Takase","year":"2014","journal-title":"Eur J Clin Invest."},{"key":"B44","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.mad.2020.111363","article-title":"Neprilysin expression and functions in development, ageing and disease","volume":"192","author":"Nalivaeva","year":"2020","journal-title":"Mech Ageing Dev."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.831541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T05:04:09Z","timestamp":1654232649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.831541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":44,"alternative-id":["10.3389\/fmed.2022.831541"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.831541","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"article-number":"831541"}}